Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1676
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    50,984.27
    -630.78 (-1.22%)
     

  • CMC Crypto 200

    1,324.35
    -72.18 (-5.17%)
     

  • S&P 500

    5,111.02
    +62.60 (+1.24%)
     

  • DOW

    38,312.74
    +226.94 (+0.60%)
     

  • CRUDE OIL

    83.85
    +0.28 (+0.34%)
     

  • GOLD FUTURES

    2,345.50
    +3.00 (+0.13%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

AccuStem Sciences, Inc.
·1-min read
AccuStem Sciences, Inc.
AccuStem Sciences, Inc.

LONDON and PHOENIX, Nov. 22, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 24,500 ACUT shares in the open market. This brings his total holding to 3,855,723 shares.

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.

Media Contact:
Jeff Fensterer
Phone: 415-640-6010
Email: jeff@accustem.com

Investor Contact:
Wendy Blosser
Email: investors@accustem.com